Adamis Pharmaceuticals Corporation 2022-04-13 Health critical FDA
Health · FDA · Recall #FDA-D-0764-2022
SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose… Recall
Issued April 13, 2022 · Adamis Pharmaceuticals Corporation
In April 2022, Adamis Pharmaceuticals Corporation recalled the SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose…, a critical health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.
What you should do
- 1 Stop using SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Adamis Pharmaceuticals Corporation to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Adamis Pharmaceuticals Corporation
- Category
- Health
- Recall date
- April 13, 2022
- Units affected
- Not reported
- Sold at
- Nationwide in the U.S.A.
- Recall number
- FDA-D-0764-2022
- Made in
- United States
- Issuing agency
- FDA
In context
- Adamis Pharmaceuticals Corporation has 2 recalls in our database, including 2 rated Critical.
- We're tracking 3,576 Health recalls in our database.
- This is the 870th Health recall we've logged in 2022.